van Lijnschoten G - Search Results

1

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.

Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VEPP, Rutten HJT, van den Brule AJC. Fariña-Sarasqueta A, et al. Among authors: van lijnschoten g, van den brule ajc. Ann Oncol. 2010 Dec;21(12):2396-2402. doi: 10.1093/annonc/mdq258. Epub 2010 May 25. Ann Oncol. 2010. PMID: 20501503 Free article.

2

A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.

van de Schoot L, Romme EA, van der Sangen MJ, Creemers GJ, van Lijnschoten G, van Driel OJ, Rutten HJ, Nieuwenhuijzen GA. van de Schoot L, et al. Among authors: van lijnschoten g, van driel oj, van der sangen mj. Ann Surg Oncol. 2008 Jan;15(1):88-95. doi: 10.1245/s10434-007-9582-6. Epub 2007 Sep 26. Ann Surg Oncol. 2008. PMID: 17896144 Free PMC article. Clinical Trial.

3

Improving lymph node detection in colon cancer in community hospitals and their pathology department in southern Netherlands.

van Steenbergen LN, van Lijnschoten G, Rutten HJ, Lemmens VE, Coebergh JW. van Steenbergen LN, et al. Among authors: van lijnschoten g. Eur J Surg Oncol. 2010 Feb;36(2):135-40. doi: 10.1016/j.ejso.2009.05.012. Epub 2009 Jul 2. Eur J Surg Oncol. 2010. PMID: 19576723

4

Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.

Fariña-Sarasqueta A, van Lijnschoten G, Rutten HJ, van den Brule AJ. Fariña-Sarasqueta A, et al. Among authors: van den brule aj, van lijnschoten g. Cancer Chemother Pharmacol. 2010 Nov;66(6):1167-71. doi: 10.1007/s00280-010-1403-0. Epub 2010 Jul 28. Cancer Chemother Pharmacol. 2010. PMID: 20665215 Free article.

5

SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics.

Fariña Sarasqueta A, Moerland E, de Bruyne H, de Graaf H, Vrancken T, van Lijnschoten G, van den Brule AJ. Fariña Sarasqueta A, et al. Among authors: van den brule aj, van lijnschoten g. J Mol Diagn. 2011 Mar;13(2):199-205. doi: 10.1016/j.jmoldx.2010.10.006. J Mol Diagn. 2011. PMID: 21354055 Free PMC article.

6

PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.

Fariña Sarasqueta A, Zeestraten EC, van Wezel T, van Lijnschoten G, van Eijk R, Dekker JW, Kuppen PJ, Goossens-Beumer IJ, Lemmens VE, van de Velde CJ, Rutten HJ, Morreau H, van den Brule AJ. Fariña Sarasqueta A, et al. Among authors: van den brule aj, van lijnschoten g, van eijk r, van wezel t, van de velde cj. Cell Oncol (Dordr). 2011 Dec;34(6):523-31. doi: 10.1007/s13402-011-0054-4. Epub 2011 Aug 10. Cell Oncol (Dordr). 2011. PMID: 21830111

7

Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?

Fariña Sarasqueta A, van Lijnschoten G, Lemmens VE, Rutten HJ, van den Brule AJ. Fariña Sarasqueta A, et al. Among authors: van den brule aj, van lijnschoten g. Mol Diagn Ther. 2011 Oct 1;15(5):277-83. doi: 10.1007/BF03256419. Mol Diagn Ther. 2011. PMID: 21958378

8

Variation in circumferential resection margin: Reporting and involvement in the South-Netherlands.

Homan J, Bökkerink GM, Aarts MJ, Lemmens VE, van Lijnschoten G, Rutten HJ, Wijsman JH, Nagtegaal ID, de Wilt JH. Homan J, et al. Among authors: van lijnschoten g. Eur J Surg Oncol. 2015 Nov;41(11):1485-92. doi: 10.1016/j.ejso.2015.07.015. Epub 2015 Jul 29. Eur J Surg Oncol. 2015. PMID: 26251342

9

Preliminary results of a cohort study of induction chemotherapy-based treatment for locally recurrent rectal cancer.

van Zoggel DMGI, Bosman SJ, Kusters M, Nieuwenhuijzen GAP, Cnossen JS, Creemers GJ, van Lijnschoten G, Rutten HJT. van Zoggel DMGI, et al. Among authors: van lijnschoten g. Br J Surg. 2018 Mar;105(4):447-452. doi: 10.1002/bjs.10694. Epub 2017 Nov 23. Br J Surg. 2018. PMID: 29168556

10

Improved Outcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer.

Voogt ELK, van Zoggel DMGI, Kusters M, Nieuwenhuijzen GAP, Bloemen JG, Peulen HMU, Creemers GJM, van Lijnschoten G, Nederend J, Roef MJ, Burger JWA, Rutten HJT. Voogt ELK, et al. Among authors: van lijnschoten g, van zoggel dmgi. Ann Surg Oncol. 2020 Sep;27(9):3503-3513. doi: 10.1245/s10434-020-08362-4. Epub 2020 Mar 19. Ann Surg Oncol. 2020. PMID: 32193717

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

41 results

Search Page